Eli Lilly (LLY) showed Omvoh delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease

Eli Lilly's announcement regarding the durable efficacy of Omvoh over three years for treating Crohn's disease suggests a strong ongoing value proposition for its treatment portfolio.

Newsquawk StaffPublished On the live feed at 2 more headlines followed before this page went public
Newsquawk headlinesUTC

White House says trade agreement with Indonesia signed today

Moncler (MONC IM) says all regions grew positively in January and February, with strong performance in Asia and the US

Eli Lilly (LLY) showed Omvoh delivered durable efficacy through three years in adults with moderately to severely active Crohn's disease

Fitch expects oil price will stay above fiscal break-even levels for all GCC sovereigns, except Bahrain, Saudi and more marginally, Oman

Reddit (RDDT) testing new AI-powered search feature that turns community recommendations into action

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This sustained effectiveness could bolster investor confidence, positively influence market sentiment toward the stock, and potentially position LLY favorably against competitors in the pharmaceuticals space. Watch for how this news might impact trading volumes and stock price in both the US and European sessions.

Related headlines

The whole workspace, free to try.

Try it free